Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, Sichuan, China.
Molecules. 2021 Mar 19;26(6):1718. doi: 10.3390/molecules26061718.
The incidence and prevalence of inflammatory bowel disorders (IBD) are increasing around the world due to bacterial infection, abnormal immune response, etc. The conventional medicines for IBD treatment possess serious side effects. (), a traditional Chinese medicine, has been used to treat arthritis, fever, aches, inflammation, and other diseases. This study aimed to evaluate the anti-inflammatory effects of oligosaccharides from (OPA) and its possible mechanisms in vivo. OPA were purified and biochemical characterization was analyzed by HPGPC, HPLC, FT-IR, and GC-MS. Acute colitis mice model was established, the acute toxicity and anti-inflammatory activity were tested in vivo. The results showed OPA with molecular mass of 1.0 kDa were composed of 83% glucose, 6% galactose, 11% xylose, and the backbone was (1→4)-Glcp. OPA had potent antioxidant activities in vitro and significantly alleviated the clinical symptoms of colitis, relieved colon damage without toxic side effects in vivo. OPA exhibited anti-inflammatory activity by regulating Th1/Th2, reducing oxidative stress, preserving intestinal barrier integrity, and inhibiting TLR4/MAPK/NF-κB pathway. Moreover, OPA protected gut by increasing microbial diversity and beneficial bacteria, and reducing pathogenic bacteria in feces. OPA might be the candidate of complementary and alternative medicines of IBD with low-cost and high safety.
由于细菌感染、免疫异常等原因,全球炎症性肠病(IBD)的发病率和患病率正在上升。IBD 的常规治疗药物具有严重的副作用。()是一种中药,用于治疗关节炎、发热、疼痛、炎症等疾病。本研究旨在评估(OPA)寡糖的抗炎作用及其在体内的可能机制。通过 HPGPC、HPLC、FT-IR 和 GC-MS 对 OPA 进行了纯化和生化特性分析。建立了急性结肠炎小鼠模型,在体内测试了急性毒性和抗炎活性。结果表明,分子量为 1.0 kDa 的 OPA 由 83%葡萄糖、6%半乳糖、11%木糖组成,其骨架为(1→4)-Glcp。OPA 具有体外抗氧化活性,能显著缓解结肠炎的临床症状,减轻结肠损伤,无体内毒性副作用。OPA 通过调节 Th1/Th2、减轻氧化应激、保持肠道屏障完整性和抑制 TLR4/MAPK/NF-κB 通路发挥抗炎作用。此外,OPA 通过增加微生物多样性和有益细菌,减少粪便中的致病菌来保护肠道。OPA 可能是一种低成本、高安全性的 IBD 辅助和替代药物的候选药物。